About this trial
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
Patient Profile
Where’s this trial being run?
Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre, St Luke’s Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | DASL HiCaP |
|---|---|
| Number: | CTRIAL-IE 19-32 |
| Full Title: | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. |
| Principal Investigator: | Prof Ray McDermott |
|---|---|
| Type: | Collaborative |
| Sponsor: | EU Sponsor- Cancer Trials Irelamd |
| Recruitment Started: |
Global: March 2021 Ireland: 7th July 2021 |
| Global Recruitment Target: | 1100 |
|---|---|
| Ireland Recruitment Target: | 200 |